Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five
Regeneron Pharmaceuticals Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five decreased by 5.7% to $9.64B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 19.9%, from $8.04B to $9.64B. Over 5 years (FY 2020 to FY 2025), Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five shows an upward trend with a 34.8% CAGR.
Analysis
How to read this metric
Provides visibility into medium-term cash flow availability from the investment portfolio.
Detailed definition
This metric represents the fair value of debt securities in the available-for-sale portfolio maturing between one and fi...
Peer comparison
Standard maturity profile disclosure for utilities with structured investment portfolios.
other_available_for_sale_securities_debt_maturities_afte_540252Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.50B | $4.26B | $5.59B | $6.05B | $5.54B | $4.84B | $5.38B | $5.00B | $5.28B | $4.83B | $4.41B | $6.18B | $6.55B | $7.18B | $7.80B | $8.04B | $8.57B | $9.52B | $10.22B | $9.64B |
| QoQ Change | — | +70.5% | +31.2% | +8.2% | -8.3% | -12.7% | +11.2% | -7.2% | +5.7% | -8.5% | -8.6% | +40.1% | +5.9% | +9.7% | +8.7% | +3.0% | +6.6% | +11.0% | +7.4% | -5.7% |
| YoY Change | — | — | — | — | +121.7% | +13.6% | -3.7% | -17.3% | -4.7% | -0.2% | -18.0% | +23.8% | +24.0% | +48.7% | +76.8% | +30.0% | +30.9% | +32.5% | +31.0% | +19.9% |
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, after year one through five?
- Regeneron Pharmaceuticals (REGN) reported debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, after year one through five of $9.64B in Q1 2026.
- How has Regeneron Pharmaceuticals's debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, after year one through five changed year-over-year?
- Regeneron Pharmaceuticals's debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, after year one through five increased by 19.9% year-over-year, from $8.04B to $9.64B.
- What is the long-term trend for Regeneron Pharmaceuticals's debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, after year one through five?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, after year one through five has grown at a 34.8% compound annual growth rate (CAGR), from $2.30B to $10.22B.
- What does debt securities, available-for-sale, fair value, maturity, allocated and single maturity date, after year one through five mean?
- The value of debt investments that will mature between one and five years from now.